Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital downgrades Greggs, says there's little to stimulate the shares

(Sharecast News) - Shore Capital downgraded Greggs on Wednesday to 'hold' from 'buy' saying that as investment reaches its peak, it sees little to stimulate the shares. The broker said it still believes Greggs is a very high quality business with an excellent management team and a value/quality proposition that continues to positively stand out in the UK food-to-go market.

"We also believe that growth opportunities do exist and that the group could be a materially bigger business on a five-year view albeit the 'peak' Greggs question is likely to be revisited periodically."

That said, Shore expects the financial performance to be more subdued than in recent years and versus what it anticipated at the time of the upgrade.

"We see the shares being dull for a couple of years, with limited catalysts to drive material upside," it said. "We concede we went too early in January in turning positive and downgrade our recommendation to hold."

At 0900 BST, the shares were down 1.6% at 2,084p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.